2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
64
Gastrointestinal
52
Thoracic
30
Gynecologic
29
Genitourinary
28
Other hematologic neoplasm
21
Tumor-Agnostic
18
Other solid neoplasm
17
Lymphoid
17
Other
14
Dermatologic
10
Head & Neck
7
Sarcoma
6
Other neoplasm
5
CNS
5
Plasma cell
3
Myeloid
1
Endocrine
1
Conditions
Neoplasms
1
Carcinoma, Neuroendocrine
1
Interventions
Everolimus
61
lutetium Lu 177 dotatate
53
Magnetic Resonance Spectroscopy
39
pembrolizumab
31
Temozolomide
31
Cisplatin
29
Nivolumab
26
Octreotide
25
lanreotide
24
gallium Ga 68 dotatate
24
cabozantinib
22
pasireotide
21
lenvatinib
20
3-Iodobenzylguanidine
20
Etoposide
19
Sunitinib
18
Specimen Handling
18
Paclitaxel
18
Carboplatin
18
Capecitabine
18
surufatinib
16
Bevacizumab
16
trametinib
15
dabrafenib
15
Sorafenib
14
Doxorubicin
14
Ipilimumab
13
Thyrotropin Alfa
12
Surgical Procedures, Operative
12
Injections
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Methods
×
Endocrine
×
Clear all
NCT04478175
2022-11-17
DParcoursDig
Institut Curie
Phase NA
Completed
30 enrolled